Related Experiment Video
Updated: Aug 13, 2026

Fabrication and Testing of Catalytic Aerogels Prepared Via Rapid Supercritical Extraction
Published on: August 31, 2018
AEOL-10150 (Aeolus)
1Department of Clinical Neurosciences, Royal Free and University College Medical School, University College London, Rowland Hill Street, London NW3 2PF, UK. r.orrell@medsch.ucl.ac.uk
Abstract:
AEOL-10150, a small-molecule antioxidant analogous to the catalytic site of superoxide dismutase, is under development by Aeolus (formerly Incara) as a potential subcutaneous treatment for amyotrophic lateral sclerosis (ALS), stroke, spinal cord injury, lung inflammation and mucositis. The compound is currently undergoing a phase I clinical trial for ALS. In October 2005, the company had applied for Fast Track status, and planned to submit a special protocol assessment for a pivotal phase II/III trial.
Related Concept Videos
Archimedes' Principle
Faraday Disk Dynamo
Coriolis Force
Plane Electromagnetic Waves II
Plane Electromagnetic Waves I
The EM field is assumed to be a...
Wind Turbine Machine Models
Induction machines interact through the rotating magnetic field generated by the stator and the rotor. The key parameter is slip, which is the difference between synchronous speed and rotor speed relative to synchronous speed. Slip is...
